Aventis submits additional Ketek information
Executive Summary
Aventis submits additional analysis of clinical studies and postmarketing surveillance data in response to FDA's Jan. 24 "approvable" letter for antibiotic Ketek (telithromycin). The company filed additional safety data in 2002 following a June 2001 "approvable" letter (1"The Pink Sheet" Nov. 4, 2002, p. 16)...
You may also be interested in...
Aventis Ketek Will Return To FDA Advisory Committee Jan. 8
FDA's Anti-Infective Drugs Advisory Committee will review the safety profile of Aventis' Ketek (telithromycin) on Jan. 8, Exec VP-Commercial Operations Thierry Soursac told an investor conference call Oct. 29
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: